(12) **Translation of European patent specification**

(11) **NO/EP 3380086 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 31/196 (2006.01)
A61K 9/48 (2006.01)
A61K 31/138 (2006.01)
A61K 31/192 (2006.01)
A61K 31/195 (2006.01)
A61K 31/277 (2006.01)
A61K 31/4166 (2006.01)
A61K 31/4196 (2006.01)
A61K 31/454 (2006.01)
A61K 31/4545 (2006.01)
A61K 31/5685 (2006.01)
A61K 31/58 (2006.01)
A61K 31/69 (2006.01)
A61K 45/06 (2006.01)
A61P 35/00 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2022.01.24
(80)	Date of The European Patent Office Publication of the Granted Patent	2021.10.13
(86)	European Application Nr.	16869301.8
(86)	European Filing Date	2016.11.23
(87)	The European Application's Publication Date	2018.10.03
(30)	Priority	2015.11.25, US, 201562260098 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
(73)	Proprietor	The Johns Hopkins University, 3400 North Charles Street, Baltimore, MD 21218, USA IO Therapeutics, Inc., 9450 Pinecrest Drive, Unit 9497, Spring, TX 77380, USA
(72)	Inventor	GHIAUR, Gabriel, 3400 N. Charles Street, Baltimore, MD 21218, USA JONES, Richard, J., 3400 N. Charles Street, Baltimore, MD 21218, USA ALONSO, Salvador, 449 Canal St.Apt. 308, Somerville, MA 02145, USA CHANDRARATNA, Roshantha, A., 26242 Via Corrizo, San Juan Capistrano, CA 92675, USA

(74) Agent or Attorney CURO AS, Vestre Rosten 81, 7075 TILLER, Norge

(54) Title **CYP26-RESISTANT RAR-ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER**

(56) References Cited:

US-B2- 6 387 950
US-B1- 6 534 544
WO-A2-2008/091620
HASHIMOTO Y ET AL: "CORRELATION OF DIFFERENTIATION-INDUCING ACTIVITY OF RETINOIDS ON HUMAN LEUKEMIA CELL LINES HL-60 AND NB4", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOL, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 121, no. 11, 1 January 1995 (1995-01-01), pages 696-698, XP009002752, ISSN: 0171-5216, DOI: 10.1007/BF01218530
JAE PARK ET AL: "Emerging new approaches for the treatment of acute promyelocytic leukemia", THERAPEUTIC ADVANCES IN HEMATOLOGY, vol. 2, no. 5, 1 October 2011 (2011-10-01) , pages 335-352, XP055606827, GB ISSN: 2040-6207, DOI: 10.1177/2040620711410773
THATCHER ET AL.: 'The role of CYP26 enzymes in retinoic acid clearance' 01 August 2010, pages 1 - 21, XP008169838
SALVADOR ALONSO ET AL: "Human bone marrow niche chemoprotection mediated by cytochrome P450 enzymes", ONCOTARGET, vol. 6, no. 17, 20 June 2015 (2015-06-20), XP055607121, DOI: 10.18632/oncotarget.3614
CHEE ET AL.: 'ATRA and the specific RARalpha agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells' LEUKEMIA. vol. 27, 11 December 2012, pages 1369 - 1380, XP055386354
ORITA ET AL.: 'Modifying Effects of 1'-Acetoxychavicol Acetate (ACA) and the Novel Synthetic Retinoids Re-80, Am-580 and Am-55P in a Two-Stage Carcinogenesis Model in Female Rats' TOXICOLOGIC PATHOLOGY. vol. 32, March 2004, pages 250 - 257, XP055386373
BEARD ET AL.: 'Synthesis and biological activity of retinoic acid receptor-alpha specific amides' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS. vol. 12, 03 November 2002, pages 3145 - 3148, XP008010813
Salvador Alonso ET AL: "Bone Marrow Niche - Multiple Myeloma Cross-Talk Generates Bortezomib Resistance - 57th Annual Meeting&Exposition", Blood Journal, 7 December 2015 (2015-12-07), XP055607123, Retrieved from the Internet: URL:http://www.bloodjournal.org/content/12 6/23/914?sso-checked=true [retrieved on 2019-07-18]
MARIKAR ET AL.: 'Retinoic Acid Receptors Regulate Expression of Retinoic Acid 4-Hydroxylaso that Specifically Inactivates All-Trans Retinoic Acid in Human Keratinocyte HaCaT Cells' JOURNAL OF INVESTIGATIVE DERMATOLOGY. vol. 111, September 1998, pages 434 - 439, XP055386358
OIKAWA ET AL.: 'Three novel synthetic retinoids, Re 80, Am 580 and Am 80, all exhibit anti-angiogenic activity in vivo' EUROPEAN JOURNAL OF PHARMACOLOGY vol. 249, 02 November 1993, pages 113 - 116, XP023769723
SUGANUMA MASAMI ET AL: "Highlights of the Twelfth Japan-Korea Joint Symposium on Cancer and Ageing Research", JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 141, no. 11, 29 March 2015 (2015-03-29), pages 1953-1961, XP035547187, ISSN: 0171-5216, DOI: 10.1007/S00432-015-1959-5 [retrieved on 2015-03-29]

M. YING ET AL: "Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid-Induced Differentiation by Modifying the RAR /STAT1 Axis", MOLECULAR CANCER THERAPEUTICS, vol. 12, no. 2, 1 February 2013 (2013-02-01), pages 195-206, XP055606848, US ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-12-0433
T SANDA ET AL: "Antimyeloma effects of a novel synthetic retinoid Am80 (Tamibarotene) through inhibition of angiogenesis", LEUKEMIA, vol. 19, no. 6, 1 June 2005 (2005-06-01), pages 901-909, XP055606824, London ISSN: 0887-6924, DOI: 10.1038/sj.leu.2403754
BINGZONG LI ET AL: "The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 290, no. 50, 19 October 2015 (2015-10-19), pages 29854-29868, XP055606853, US ISSN: 0021-9258, DOI: 10.1074/jbc.M115.664953

Patentkrav

1. Kombinasjon for anvendelse i en framgangsmåte for behandling av en hematologisk malignitet, hvori kombinasjonen omfatter en virksom dose av en CYP26-resistent selektiv agonist for retinsyrereseptor-alfa (RARα) og en proteasominhibitor og valgfritt, i det minste ett ekstra anti-kreft middel, hvori den CYP26-resistente selektiv agonist for retinsyrereseptor-alfa (RARα) er en forbindelse som oppviser strukturen med formel III



III

(IRX5183), og

hvori det valgfrie i det minste ett ekstra anti-kreftmiddel er valgt fra listen bestående av etoposid, et antrasyklin, idarubicin, daunorubicin, mitoxantron, cytarabin, en kombinasjon av et antrasyklin, cytarabin og etoposid, et demetyleringsmiddel, 5-azacytidin, decitabin, en tyrosinkinaseinhibitor, en BCR-ABL-inhibitor, en Flt3-inhibitor, en cKit-inhibitor, en IDH1/2-inhibitor, en JAK2-inhibitor, en BTK-inhibitor, anti-CD33-mAb, anti-CD20-mAb, anti-CD19-mAb, anti-CD30-mAb, en PD1-inhibitor, en CTL4-inhibitor, lenolidamid, pomalidomid, syklofosfamid, bevacizumab, vinkristin, et kortikosteroid, bleomycin, adriamycin, bendamustin, fludarabin, G-CSF, GM-CSF, Epo, og kombinasjoner av samme, hvori tumor-belastningen reduseres som et resultat av behandlingen;

hvori framgangsmåten omfatter administrering av kombinasjonen til et subjekt med behov;

hvori proteasom-inhibitoren er bortezomib, og

hvori den hematologiske malignitet er multippel myelom.